Health
Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer – Medscape
The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.
After a modest early signal of benefit, candesartan cilexetil (Atacand, Cheplapharm) showed no effect on key markers of heart health 2 years after treatment in patients with early-stage breast cancer in the randomized PRADA trial.
The 2015 study was hailed at the time as the largest randomized trial in breast cancer to look at the effects of angiotensin-receptor blockade with candesartan and the -blocker metoprolol, both against placebo, on cardiac dysfunction. The 120 patients received adjuvant…
-
Noosa News16 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
Noosa News23 hours agoIpswich landmark shuts down after 50 years due to storms, costs and lack of new movies
-
Noosa News18 hours agoFuel tanker racing to unload in Darwin ahead of Tropical Cyclone Fina
-
Noosa News24 hours agoThe wait to taste new Queensland-grown purple-skinned pineapples